Business Performance Review

Market and Therapeutic Area Mix Market Mix 18% 19% 25% 22% 20% Therapeutic Area Mix 29% 34% 32% 39% 39% 8% Emerging Markets 7% 53 14% 82% 81% 5% 6% 3% 5% 6% 4% 3% 4% 17% 12% 18% 15% dido Others Pain Management Diabetes 75% 78% 80% CNS ■Regulated Markets CVS 42% 40% 43% 36% 38% Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Regulated markets contribution is at 80% in Q2FY24 driven by growth in US, LATAM, Europe and India During Q2FY24, regulated market contributed 80% of the total portfolio compared to 75% in Q2FY23 CVS and CNS portfolio continued to deliver a strong growth Our key focused area of chronic therapies contributed 68% of the revenue in Q2FY24 11 Є Glenmark LIFE SCIENCES

View entire presentation